Dyne Therapeutics Reports Quarterly Earnings, Surpasses Expectations

Dyne Therapeutics (NASDAQ:DYN) released its quarterly earnings results on Thursday. The report showed an earnings per share (EPS) of ($0.88), which exceeded analysts' expectations of ($0.92) by $0.04, according to Zacks.

Dyne Therapeutics Stock Performance

On Thursday, Dyne Therapeutics stock fell by $0.62, closing at $13.17. Approximately 2,055,570 shares were traded, which is slightly lower than the company's average trading volume of 2,280,310 shares. Over the past twelve months, the stock has reached a low of $13.05 and a high of $47.45. The stock's 50-day moving average is currently $17.19, while the 200-day moving average stands at $27.93. Dyne Therapeutics has a market capitalization of $1.34 billion, a price-to-earnings ratio of -3.70, and a beta of 1.11.

Insider Trading Activity at Dyne Therapeutics

In related news, senior vice president Richard William Scalzo sold 1,455 shares of the company's stock on December 11. The shares were sold at an average price of $28.12, totaling approximately $40,914.60. After this transaction, Scalzo retains ownership of 127,078 shares, valued at around $3,573,433.36, marking a 1.13% decrease in his stake. This transaction was disclosed in a legal filing with the SEC. Additionally, insider Oxana Beskrovnaya sold 2,334 shares on the same day for a total value of about $65,632.08, also at an average price of $28.12. After this sale, she holds 201,685 shares valued at roughly $5,671,382.20, representing a 1.14% ownership decrease. Over the last ninety days, insiders have sold a combined total of 6,387 shares valued at $142,789. Currently, corporate insiders own 20.77% of the company's stock.

Analyst Ratings and Outlook

Multiple analysts have recently provided their reports on Dyne Therapeutics. HC Wainwright reiterated a "buy" rating with a price target of $55.00 on January 10. Likewise, Chardan Capital also reaffirmed a "buy" rating with a price objective of $50.00 on the same date. Guggenheim issued a "buy" rating on January 24, while Robert W. Baird initiated coverage on December 13, indicating an "outperform" rating with a target of $46.00. In addition, Baird R W upgraded Dyne Therapeutics to a "strong-buy" rating on December 12. One of the analysts has rated the stock as a sell, one as a hold, while ten have assigned buy ratings, and two have given strong buy ratings. According to MarketBeat, the stock currently holds a consensus rating of "Moderate Buy" with an average target price set at $49.91.

About Dyne Therapeutics

Dyne Therapeutics, Inc. is a biotechnology company specializing in clinical-stage treatments for muscle diseases. The company's focus lies in developing therapeutics for genetically driven muscle disorders in the US. Its ongoing projects involve treatments for various conditions, including myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and other rare muscle diseases utilizing its FORCE platform to deliver disease-modifying therapies.

Earnings, Stocks, Company